Medial prefrontal cortical D2 and striatolimbic D4 dopamine receptors: Common targets for typical and atypical antipsychotic drugs

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 22, Issue 4, 1998, Pages 693-707

  Tarazi, Frank I ^a,c   Yeghiayan, Sylva K ^a   Neumeyer, John L ^b   Baldessarini, Ross J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Alcohol and Drug Abuse Research Center   (United States)

^c MCLEAN HOSPITAL   (United States)

Author keywords

Antipsychotics; Autoradiography; Clozapine; Dopamine receptors; Fluphenazine; S(+) N n propylnorapomorphine

Indexed keywords

CLOZAPINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; FLUPHENAZINE; PROPYLNORAPOMORPHINE; RECEPTOR SUBTYPE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTORADIOGRAPHY; CAUDATE NUCLEUS; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; INTRAPERITONEAL DRUG ADMINISTRATION; LIMBIC CORTEX; MALE; NONHUMAN; NUCLEUS ACCUMBENS; OLFACTORY BULB; PREFRONTAL CORTEX; PSYCHOSIS; PUTAMEN; RAT; RECEPTOR OCCUPANCY; STRIATE CORTEX;

AMYGDALA; ANIMALS; ANTIPSYCHOTIC AGENTS; AUTORADIOGRAPHY; MALE; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE; VISUAL CORTEX;

EID: 0032079044     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(98)00033-5     Document Type: Article

References (52)

1. ALBIN, R. L., YOUNG, A. B., and PENNEY, J. B. (1989) The functional anatomy of basal ganglia disorders. Trends Neurosci. 12: 366-375.
2. 1 antagonists. Naunyn-Schmiedeberg's Arch. Pharmacol. 338: 162-168.
3. BALDESSARINI, R. J. (1996) Drugs and the treatment of psychiatric disorders. In: Goodman and Gilman's The Pharmacological Basis of Therapeutics, ninth edition, J.G. Hardman, L.E. Limbird, P.B. Molinoff, R.W. Ruddon, and A.G. Gilman (Editors), pp 399-459, New York, McGraw-Hill.
4. BALDESSARINI, R. J. (1997) Dopamine receptors and clinical medicine. In: The Dopamine Receptors, K.A. Neve and R.L. Neve (Editors), pp 457-498, Totowa, NJ, Humana Press.
5. BALDESSARINI, R. J., CAMPBELL, A., BEN-JONATHAN, N., ELLINGBOE, J., ZONG, R., and NEUMEYER, J. L. (1994) Effects of aporphine isomers on rat prolactin. Neurosci. Lett. 176: 269-271.
6. BALDESSARINI, R. J., and FRANKENBURG, F. R. (1991) Clozapine-a novel antipsychotic agent. New Engl. J. Med. 324: 746-754.
7. BALDESSARINI, R. J., and TARAZI, F. I. (1996) Brain dopamine receptors: a primer on their current status, basic and clinical. Harvard Rev. Psychiatry 3: 301-325.
8. BALDESSARINI, R. J., TARAZI, F. I., KULA, N. S., and GARDNER, D. M. (1997) Clozapine withdrawal: Serotonergic or dopaminergic mechanisms-reply. Arch. Gen. Psychiatry 54: 761-762.
9. BALDESSARINI, R. J., and TARSY, D. (1979) Relationship of the actions of neuroleptic drugs to the pathophysiology of tardive dyskinesia. Intl. Rev. Neurobiol. 21: 1-45.
10. BERGER, B., GASPAR, P., and VERNEY, C. (1991) Dopaminergic innervation of the cerebral cortex: unexpected differences between rodents and primates. Trends Neurosci. 14: 21-27.
11. CAMPBELL, A., BALDESSARINI, R. J., TEICHER, M. H., and NEUMEYER, J. L. (1986) Behavioral effects of apomorphine isomers in the rat: selective locomotor-inhibitory effects of S(+)N-n-propylnor-apomorphine. Psychopharmacology 88: 158-164.
12. CAMPBELL, A., YEGHIAYAN, S. K., BALDESSARINI, R. J., and NEUMEYER, J. L. (1991) Selective antidopaminergic effects of S(+)-N-propylnoraporphines in limbic vs extrapyramidal sites in rat brain: Comparisons with typical and atypical antipsychotic agents. Psychopharmacology 103: 323-329.
13. CAMPBELL, A., BALDESSARINI, R. J., and NEUMEYER, J. L. (1993) Altered spontaneous behavior and sensitivity to apomorphine in rats following treatment with S(+)-aporphines or fluphenazine. Psychopharmacology 111: 351-358.
14. 2 (haloperidol) antagonists in drug-naive monkeys. Psychopharmacology 107: 18-22.
15. 1 receptors. J. Pharmacol. Exp. Ther. 249: 769-776.
16. CREESE, I., BURT, D. R., and SNYDER, S. H. (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192: 481-483.
17. 1 antagonist SCH 39166 in six cases of acute psychotic states. Psychopharmacology 121: 323-327.
18. 11C]raclopride. Psychopharmacology 107: 23-29.
19. 2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology 99: S28-S31.
20. FLORIJN, W. J., TARAZI, F. I., and CREESE, I. (1997) Dopamine receptor subtypes: Differential regulation after eight months treatment with antipsychotic drugs. J. Pharmacol. Exp. Ther. 280: 561-569.
21. 1 receptor antagonism in schizophrenia: is there a reduced risk of extrapyramidal side-effects? Trends Pharmacol. Sci. 11: 406-410.
22. KEBABIAN, J. W., TARAZI, F. I., KULA, N. S., and BALDESSARINI, R. J. (1997) Compounds selective for dopamine receptor subtypes. Drug Discovery Today 2: 333-340.
23. 4-selective dopamine receptor ligand. Eur. J. Pharmacol. 331: 333-336.
24. 4 receptor. J. Med. Chem. 39: 1941-1942
25. 2-type dopamine receptors in postmortem human brain sections from normal and schizophrenic subjects. NeuroReport 7: 1945-1948.
26. 2-Family receptor distribution in human postmortem tissue: An autoradiographic study. NeuroReport 6: 2505-2512.
27. 4.4 receptors. Eur. J. Pharmacol. 301: R11-R13.
28. 2-dopaminergic receptors in the primate cerebral cortex. Proc. Natl. Acad. Sci. USA 91: 4353-4356.
29. 3 receptors. Mol. Pharmacol. 43: 749-754.
30. MEADOR-WOODRUFF, J. H., DAMASK, S. P., WANG, J., HAROUTUNIAN, V., DAVIS, K. L., and WATSON, S. J. (1996) Dopamine receptor mRNA expression in human striatum and neocortex. Neuropsychopharmacology 15: 17-29.
31. 2 dopamine receptors produced by alternative RNA slicing. Nature 342: 926-929.
32. 4 dopamine receptors in postmortem striatum from patients with schizophrenia. J. Neurosci. 15: 2186-2191.
33. NEMEROFF, C. B., KILTS, C. D., LEVANT, B., BISSETTE, G., CAMPBELL, A., and BALDESSARINI, R. J. (1991) Effects of aporphine isomers and haloperidol on regional concentrations of neurotensin in rat brain. Neuropsychopharmacology 4: 27-33.
34. NEVE, K. A., and NEVE, R. L. (editors) (1997) The Dopamine Receptors. Totowa, NJ, Humana Press.
35. 2A receptor gene: Identification of alternative transcripts and a variant donor splice site. Biochemistry 29: 1367-1371.
36. PAXINOS, F., and WATSON, C. (1982) The Rat Brain in Stereotaxic Coordinates. New York, Academic Press
37. 4 receptors in drug-treated schizophrenia. Eur. J. Pharmacol. 281: R5-R6
38. 4 receptors by 2-fold in rats. Eur. J. Pharmacol. 289: 67-72.
39. SEEMAN, P. (1980) Brain dopamine receptors. Pharmacol. Rev. 32: 229-313.
40. 4 receptors elevated in schizophrenia. Nature 365: 441-445.
41. SEEMAN, P., LEE, T., CHAU-WONG, M., and WONG, K. (1976) Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261: 717-719.
42. 4 receptors bind inactive (+)-aporphines, suggesting neuroleptic role; Sulphide not stereoselective. Eur. J. Pharmacol. 233: 173-174.
43. 3 as a target for neuroleptics. Nature 347: 146-151.
44. 3H]raclopride binding in postmortem caudate nucleus of subjects with schizophrenia or major depression. Brain Res. 681: 109-116.
45. 4 receptor. Neurosci. Lett. 199: 69-72.
46. 4-like receptors. Neuroscience 83: 169-176.
47. TARAZI, F. I., FLORIJN, W.J., and CREESE, I. (1997a) Differential regulation of dopamine receptors following chronic typical and atypical antipsychotic drug treatment. Neuroscience 78: 985-996.
48. 4 receptors in rat forebrain. NeuroReport 8: 3423-3426.
49. 4-like dopamine receptors. Neuropsychopharmacology 17: 186-196.
50. TARSY, D., and BALDESSARINI, R.J. (1973) Pharmacologically induced behavioural supersensitivity to apomorphine. Nature 245: 262-263.
51. 4 receptor gene with high affinity for the antipsychotic clozapine. Nature 350: 614-619.
52. 3H]propyl-2-aminotetralin and carbetapentane. J. Neurochem. 64: 700-710.